Radar · Life Sciences in Los Angeles
Best Life Sciences Companies in Los Angeles, United States
The 286 best Life Sciences companies in Los Angeles, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ACELYRIN.
By Riya SenguptaFinancials
286companies tracked
$3Bdisclosed funding
0unicorns
129have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × LOS ANGELES
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
402kcombined LinkedIn audience
63%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Los Angeles
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ACELYRIN Developer of drugs for immunology | $550M | 45 mo ago | 113 | 2020 | — | 20 patents Therapeutic antibodies targeting inflammatory pathways for autoimmune skin and joint diseases | — |
| 2 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 8 mo ago | — | 2019 | Mark Attanasio Co-Founder | — | — |
| 3 | Kernel Developer of multimodal brain measurement technology for neuromedicine | $158M | 30 mo ago | 60 | 2016 | — | — | — |
| 4 | C3J Therapeutics Developing phage therapeutics to combat antibiotic-resistant bacterial infections | $124M | 114 mo ago | 60 | 2006 | — | — | — |
| 5 | Octant Provider of human cell interaction platform for drug discovery | $115M | 49 mo ago | 65 65 → 68 (+5%) | 2017 | — | 52 patents High-throughput bioassays, retinal gene‑therapy compounds, cell signaling analytics, pathogen diagnostics | 1 partnership |
| 6 | Science 37 Provider of a suite solution for clinical trials for researchers | $106M | 69 mo ago | 159 159 → 298 (+87%) | 2014 | — | 245 patents Specialty surfactants and polyether polymer ingredients for cosmetics and pharmaceutical formulations. | 1 job opening |
| 7 | Prolacta Bioscience Human milk-based nutrition for vulnerable infants, improving health outcomes | $99M | 97 mo ago | 314 | 1999 | — | 231 patents Human milk-derived nutritional products and processing technologies for infant and clinical nutrition | 1 launch |
| 8 | Kite Pharma Developer of cancer immunotherapy products using genetic engineering | $98M | 98 mo ago | 17 | 2009 | — | 1,184 patents Engineering CAR‑T cells and immune‑cell vectors for targeted cancer immunotherapy | — |
| 9 | Auspex Pharmaceuticals Developer of small molecule therapeutics for neurodegenerative diseases | $92M | 149 mo ago | 37 | 2001 | — | 952 patents Osmotic drug delivery and VMAT2‑targeted therapies for movement disorder treatment | — |
| 10 | Capricor Therapeutics Developer of regenerative medicine for cardiovascular disorders | $84M | 78 mo ago | 55 | 2005 | — | — | — |
| 11 | Armata Pharmaceuticals Developer of phage therapeutics | $73M | 50 mo ago | 69 69 → 74 (+7%) | 1989 | Deborah Birx CEO | — | — |
| 12 | Bionaut Labs Developer of miniature robots for drug delivery | $63M | 42 mo ago | 50 | 2015 | Alex Shpunt Co-Founder | 76 patents Patents concentrated in health & consumer products | — |
| 13 | Puma Biotechnology Developer of tyrosine kinase inhibitor for the treatment of breast cancer | $60M | 51 mo ago | 193 193 → 258 (+34%) | 2010 | — | — | — |
| 14 | ImaginAb Immune imaging technology for cancer and autoimmune disease management | $60M | 60 mo ago | 17 17 → 12 (-29%) | 2007 | — | 131 patents Therapeutic antibodies targeting CD8, DLL3, and integrin αvβ6 for cancer immunotherapy | — |
| 15 | Health-Ade Bubbly probiotic tea and gut-healthy soda for a happier gut | $54M | 66 mo ago | 135 135 → 152 (+13%) | 2012 | Vanessa Dew Co-Founder | — | 2 launchs |
| 16 | Appia Bio Developer of cell therapies | $52M | 61 mo ago | 39 | 2020 | JeenJoo Kang CEO | — | — |
| 17 | MannKind Corp Developer of small-molecule drugs | $50M | 63 mo ago | 322 | 1991 | Michael Castagna Chief Executive Officer | 1,985 patents Dry powder inhaler devices and pulmonary drug formulation/composition technologies. | 1 internship · 1 award |
| 18 | Pictor Labs AI-based solutions for pathological image analysis | $49M | 17 mo ago | 29 | 2019 | Yair Rivenson Co-Founder & CEO | 6 patents AI-powered digital pathology: virtual staining, immunostain analysis, and analyte detection. | — |
| 19 | Second Sight Provider of an implantable visual prosthetic for blind individuals | $37M | 47 mo ago | 14 | 2000 | Adam Mendelsohn CEO | 802 patents AI-driven cyber risk analytics and implantable brain-computer interface neurotechnology solutions. | — |
| 20 | Trethera Developer of small molecule cancer therapeutics that target DNA replication and integrity 29Funding top 30%Patents top 37%Moat top 37%Product top 41% All 9 signals ▾Fundingtop 30% Patentstop 37% Moattop 37% Producttop 41% Innovationtop 42% Techtop 47% Talentbottom 49% Globalbottom 33% Marketbottom 18% Funding: Raised $31.0M across 20 rounds · 20 rounds over 11 yrs (1.8/yr) Patents: 15 patents matched (strict assignee match) · 15 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 8 mo ago | 3 | 2013 | Ken Schultz Chairman & CEO | 15 patents Patents concentrated in health & consumer products | — |
| 21 | Pelage Pharmaceuticals Developer of therapeutics for hair loss treatment in men and women | $31M | 9 mo ago | — | 2018 | William Lowry Co-Founder & President | — | — |
| 22 | Aadi Bioscience Precision medicine company improving lives with mTOR-driven disease therapies | $23M | 15 mo ago | 95 | 2008 | Neil Desai CEO & Chairman | — | — |
| 23 | Needed Provider of nutritional supplements for prenatal care | $23M | 33 mo ago | 54 | 2017 | Julie Sawaya Co-Founder and Co-CEO | — | — |
| 24 | Aneuvo Developer of a medical device for the treatment of spinal cord injuries 32Growth top 35%Funding top 39%Tech top 49%Talent bottom 49% All 6 signals ▾Growthtop 35% Fundingtop 39% Techtop 49% Talentbottom 49% Marketbottom 25% Globalbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $22M | 3 mo ago | — | 2016 | Yi Lo CEO | — | — |
| 25 | NeOnc Technologies Developer of drug delivery methods for pharma-based therapeutics | $19M | 10 mo ago | 4 | 2008 | — | 48 patents Monoterpene-derived anticancer drug formulations, especially perillyl alcohol derivatives. | — |
| 26 | Sensydia Cardio-respiratory monitoring device 27Funding top 36%Product top 36%Moat top 38%Innovation top 44% All 10 signals ▾Fundingtop 36% Producttop 36% Moattop 38% Innovationtop 44% Talentbottom 49% Patentsbottom 48% Techbottom 44% Globalbottom 33% Marketbottom 22% Newsbottom 22% Funding: Raised $17.8M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) Product: 6 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 27/100 | $18M | 14 mo ago | 8 | 2015 | Anthony Arnold President & Chief Executive Officer | 4 patents Non‑invasive cardiac acoustic analysis and multi‑sensor pulmonary pressure monitoring devices | — |
| 27 | MAX BioPharma Biopharmaceutical company pioneering Oxysterol Therapeutics® for debilitating and fatal human diseases | $10M | 15 mo ago | 5 | 2010 | Farhad Parhami D President & CEO | — | — |
| 28 | Partillion Developer of single-cell assays for cell analysis | $10M | 14 mo ago | 6 | 2020 | — | — | 2 launchs |
| 29 | Immix Biopharma Developer of therapeutics for amyloidosis, autoimmune diseases, and oncology indications 53Product top 14%News top 24%Growth top 32%Funding top 34% All 12 signals ▾Producttop 14% Newstop 24% Growthtop 32% Fundingtop 34% Innovationtop 39% Patentstop 41% Moattop 45% Techtop 47% Fin. healthtop 49% Talentbottom 49% Marketbottom 38% Globalbottom 36% Product: 5 distinct product lines · Company stage: Public News: 5 BI events in 12 mo (of 16 tracked, 7 types) · +150% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 9 mo ago | 11 | 2012 | Ilya Rachman Co-Founder & CEO | 25 patents Targeted nanoparticle delivery of therapeutic agents for cancer and inflammatory diseases | — |
| 30 | Illuminant Developer of a surgical navigation system using augmented reality technology | $9M | 1 mo ago | 9 | 2021 | — | — | — |
| 31 | Supergut Internet-first brand offering multi-category nutritious products | $8M | 15 mo ago | 30 | 2019 | Marc Washington Founder & CEO | — | — |
| 32 | StrokeDx Developer of a portable device for the diagnosis of stroke | $7M | 24 mo ago | 3 | 2021 | Alexander Ballatori Co-Founder & CEO | 14 patents Noninvasive brain monitoring sensors and coil positioning systems for handheld diagnostics. | — |
| 33 | SpineX Developer of a medical device for neurological conditions | $6M | 9 mo ago | 15 | 2018 | — | 5 patents Non‑invasive wearable CNS neuromodulation devices for spinal pain and motor disorder therapy | — |
| 34 | Sanguine Building a databank of patient-derived data for advanced research | $6M | 31 mo ago | 73 73 → 100 (+37%) | 2010 | Brian Neman Co-Founder & CEO | 3 patents Integration of negative pressure wound therapy with ostomy faceplate devices | 6 job openings · 1 launch |
| 35 | Essenvia Provider of regulatory information management (RIM) platform for the MedTech industry | $5M | 31 mo ago | 19 | 2018 | Soumya Mahapatra Founder & CEO | 3 patents Patents concentrated in computing, sensing & instrumentation | — |
| 36 | Rarity PBC Developer of gene therapies for rare genetic diseases | $5M | 7 mo ago | — | 2023 | Donald Kohn Co-Founder | — | — |
| 37 | LighthouseAI Provider of software and services for pharmaceutical state licensing and compliance 40Growth top 35%Tech top 39%Funding top 45%Talent bottom 49% All 7 signals ▾Growthtop 35% Techtop 39% Fundingtop 45% Talentbottom 49% Globalbottom 36% Marketbottom 27% Newsbottom 22% Growth: Fresh capital in last 24 mo Tech: 39 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 40/100 | $5M | 1 mo ago | 18 | 2023 | Sumeet Singh Founder & CEO | — | — |
| 38 | Kairos Pharma Developer of T-cell therapies against cancer and drug resistance | $4M | 17 mo ago | 3 | 2016 | — | — | — |
| 39 | MyoGene Bio Manufacturer of devices for muscular dystrophy treatment 8Talent top 38%Funding top 45%Global bottom 29%Market bottom 10% All 4 signals ▾Talenttop 38% Fundingtop 45% Globalbottom 29% Marketbottom 10% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $3.2M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 8/100 | $3M | 7 mo ago | 3 | 2020 | April Pyle Co-Founder | — | — |
| 40 | Symphony Biosciences Developer of drugs to treat solid tumors | $2M | 16 mo ago | 4 | 2021 | Manish Butte Co-Founder | — | — |
| 41 | Molecular Instruments Provider and developer of molecular instruments for drug development | $2M | 21 mo ago | 28 | 2018 | — | — | 2 launchs |
| 42 | SeqOnce Biosciences Provider of products & services for DNA and RNA Next Generation Sequencing sample preparation | $2M | 20 mo ago | 17 | 2014 | — | — | — |
| 43 | AesculaTech AesculaTech is a biomedical startup that uses custom chemistry and smart materials to develop adaptable and… | $2M | 14 mo ago | 2 | 2016 | Niki Bayat Co-Founder & CEO | 14 patents Advanced polymer-based drug delivery systems and injectable biomedical devices | — |
| 44 | Bexa Provider of a device for breast examination in women | $2M | 18 mo ago | — | 1997 | Joe Peterson CEO | — | — |
| 45 | The Plug Developer of plant-based hangover drinks | $2M | 8 mo ago | 40 | 2019 | — | 3 patents Advanced power management systems for electronic devices | — |
| 46 | Kannalife Provider of cannabis-based therapeutic agents for inflammation | $2M | 23 mo ago | 6 | 2010 | — | 8 patents Therapeutic functionalized 1,3‑benzene diol compounds for treating hepatic encephalopathy | — |
| 47 | Metanoia Bio Provider of platform technology to prevent diabetes | $1M | 3 mo ago | 5 | 2020 | Jake Mendelsohn Co-Founder | — | — |
| 48 | Lucendi AI-enabled smart measurement systems using computational microscopy technology for micro-object… | $1M | 7 mo ago | 5 | 2016 | Aydogan Ozcan Co-Founder | — | — |
| 49 | Voxel Healthcare Provider of clinical decision support tools for pediatric radiology | $944K | 23 mo ago | — | 2017 | Sinchai Tsao CEO | — | — |
| 50 | Hura Imaging AI-powered medical imaging software solutions improving safety, efficiency, and diagnostic quality | $250K | 16 mo ago | — | 2015 | Danny JJ Wang Founder | — | — |
Top 12 Life Sciences companies in Los Angeles
#1
Series C · Los Angeles, California · founded 2019$350Mraised▾
Series C · Los Angeles, California · founded 2019
Developer of antibody-based therapeutics for the treatment of cancer. The company's lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate for patients across multiple cancer types. Also, it is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 16%Moat
top 31%Talent
bottom 49%Market
bottom 40%Global
bottom 29%Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series C (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Oct 2025Series C$96M
- Apr 2024Series B$158.3M
- Apr 2023Series B$158M
Founders & team
Investors
Goldman Sachs Asset Management, Deep Track Capital, Moore Ventures, Cowen, Bristol-Myers Squibb, Vertex Ventures HC
#2
Series C · Los Angeles, California · founded 2016$22Mraised▾
Series C · Los Angeles, California · founded 2016
Developer of a medical device for the treatment of spinal cord injuries. The company focuses on the development of medical devices and systems to modulate the central, peripheral, autonomous, and enteric nervous systems for the treatment of spinal cord injury, multiple sclerosis, and gastrointestinal tract diseases. ExaStim is a non-invasive neuromodulation system to restore lost function.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 35%Funding
top 39%Tech
top 49%Talent
bottom 49%Market
bottom 25%Global
bottom 25%Growth: Fresh capital in last 24 mo
Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Tech: 31 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Series C$22M
Founders & team
Investors
Catcher Technology
Tech stack
CloudflareCloudflare Bot ManagementCookieyesCore-JsGoogle AnalyticsGoogle Font Api
#3
Seed · Los Angeles, California · founded 2021 · 9 employees$9Mraised▾
Seed · Los Angeles, California · founded 2021 · 9 employees
Developer of a surgical navigation system using augmented reality technology. The system projects anatomical information directly onto the patient, eliminating the need to shift attention between screens. It simplifies surgical workflow with non-invasive setup, reducing complexity and time. The technology is applicable to various care settings and specialties.
Funding rounds
- Apr 2026Seed$8.4M
- Sep 2024Grant (prize money)$295K
- Jan 2024Grant (prize money)$274.9K
Investors
National Science Foundation, Wing2Wingfoundation, National Cancer Institute, NIH, Elderberry Ventures, Soma Capital
#4
Series C · Los Angeles, California · founded 2013 · 3 employees$31Mraised▾
Series C · Los Angeles, California · founded 2013 · 3 employees
Developer of small molecule cancer therapeutics that target DNA replication and integrity. Its lead compounds target metabolic pathways that control DNA replication and signal transduction pathways that allow cells to repair DNA damage. Its lead candidate is a deoxycytidine kinase inhibitor that is currently under investigation for leukemia and solid tumors.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 30%Patents
top 37%Moat
top 37%Product
top 41%Innovation
top 42%Tech
top 47%Funding: Raised $31.0M across 20 rounds · 20 rounds over 11 yrs (1.8/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 15 patents matched (strict assignee match) · 15 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 7/10 · IP moat: 15 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 402 LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Massachusetts General Hospital) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$1.8M
- Sep 2025Grant (prize money)$610.9K
- Aug 2025Grant (prize money)$2M
- Aug 2025Grant (prize money)$995K
Founders & team
Investors
HHS, NIH
Tech stack
WordpressMysqlPhpVarnishYoast SeoApache Http Server
#5
Series A · Los Angeles, California · founded 2023 · 18 employees$4.6Mraised▾
Series A · Los Angeles, California · founded 2023 · 18 employees
Provider of software and services for pharmaceutical state licensing and compliance. The company offers software solutions for compliance requirement research and maintenance. It also provides services such as regulatory filings, accreditation support, inspection preparation, and policy development. The company serves pharmaceutical manufacturers, wholesale distributors, logistics companies, and pharmacies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Growth
top 35%Tech
top 39%Funding
top 45%Talent
bottom 49%Global
bottom 36%Market
bottom 27%Growth: Fresh capital in last 24 mo
Tech: 39 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Observability: Microsoft Clarity
Funding: Raised $4.6M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (Apr 2026)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Apr 2026Series A$8M
- Aug 2023Seed$4.6M
Founders & team
Investors
Healthy Ventures, Bertelsmann, Eileses Capital, Bluepointe Ventures, LegalTech, Boxcar Partners
Tech stack
CloudflareCloudflare Bot ManagementGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGoogle Tag Manager
#6
Series B · Los Angeles, California · founded 2018$30.8Mraised▾
Series B · Los Angeles, California · founded 2018
Developer of therapeutics for hair loss treatment in men and women. It provides a topical, non-invasive small molecule pharmacological platform that can be used to activate hair follicle stem cells and promote thick hair growth.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Series B$120M
- Aug 2024Series A$14M
- Feb 2024Series A$16.8M
Founders & team
Investors
Google Ventures, Main Street Advisors, Visionary Ventures, Arch Venture Partners, Ykbioventures.com
Tech stack
Anime.JsCloudflareCloudflare Bot ManagementCore-JsElementorGodaddy
#7
Public · Los Angeles, California · founded 2008 · 4 employees$18.7Mraised▾
Public · Los Angeles, California · founded 2008 · 4 employees
Developer of drug delivery methods for pharma-based therapeutics. The company develops intranasal inhalation of perillyl alcohol for the treatment of malignant brain cancer (gliomas). The company has secured worldwide rights to NEO100, a purified version of perillyl alcohol, and has obtained approval from the FDA to perform clinical trials in patients with recurrent Grade 4 glioma.
Funding rounds
- Aug 2025Grant (prize money)$2.5M
- Jul 2024Series A$18.3M
- Feb 2022Seed$50K
- Feb 2013Seed$24.8K
Investors
NIH, S3 Capital
Tech stack
WordpressMysqlPhpWebfactory MaintenanceNginxBunny
#8
Series B · Los Angeles, California · founded 2019 · 29 employees$48.8Mraised▾
Series B · Los Angeles, California · founded 2019 · 29 employees
AI-based solutions for pathological image analysis. It provides an AI-based tool to lab team members to analyze the tissue images responsible for causing infections, cancer, and other diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Jan 2025Series B—
- Aug 2024Series B$30M
- May 2022Series A$15.2M
- Aug 2020Seed$3.6M
Founders & team
Investors
M Ventures, SCC Soft Computer, Koc Holding, Insight Partners, LabCorp, Motus Ventures
Tech stack
CloudflareDropboxGoogle Font ApiGoogle Hosted LibrariesGoogle WorkspaceHsts
#9
Public · Los Angeles, California · founded 2012 · 11 employees$9.1Mraised▾
Public · Los Angeles, California · founded 2012 · 11 employees
Developer of therapeutics for amyloidosis, autoimmune diseases, and oncology indications. The company's product line include NXC-201, a BCMA-targeting CAR-T therapy for relapsed/refractory AL amyloidosis, multiple myeloma, and autoimmune disease and IMX-110 for solid tumors like soft tissue sarcoma.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Product
top 14%News
top 24%Growth
top 32%Funding
top 34%Innovation
top 39%Patents
top 41%Product: 5 distinct product lines · Company stage: Public
News: 5 BI events in 12 mo (of 16 tracked, 7 types) · +150% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 9k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- Sep 2025Post IPO$9.1M
- Aug 2017Series A—
Founders & team
Investors
GOOSE Capital, Mesa Verde Venture Partners
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsDiviElementor
#10
Seed · Los Angeles, California · founded 2020 · 3 employees$3.2Mraised▾
Seed · Los Angeles, California · founded 2020 · 3 employees
Manufacturer of devices for muscular dystrophy treatment
Fliar Intelligence Index™ 8how this company ranks against its industry peers
Talent
top 38%Funding
top 45%Global
bottom 29%Market
bottom 10%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $3.2M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) · Last round Seed (Nov 2025)
Global: Single-market focus (United States)
Audience (LinkedIn): 901 LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Nov 2025Seed$400K
- May 2025Grant (prize money)$1.3M
- Sep 2024Grant (prize money)$110K
- May 2023Seed—
Founders & team
Investors
MassChallenge, CureDuchenne, HHS, Parent Project Muscular Dystrophy
#11
Series A · Los Angeles, California · founded 2015 · 8 employees$17.8Mraised▾
Series A · Los Angeles, California · founded 2015 · 8 employees
Cardio-respiratory monitoring device. It develops a wireless, non-invasive Cardio-Respiratory monitoring device that will help patients measure real-time heart function. The company is operating in stealth mode.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 36%Product
top 36%Moat
top 38%Innovation
top 44%Talent
bottom 49%Patents
bottom 48%Funding: Raised $17.8M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) · Last round Grant (prize money) (Apr 2025)
Product: 6 distinct product lines · Company stage: Series A
Moat: Editorial + unicorn rating 7/10 · IP moat: 4 patents
Audience (LinkedIn): 695 LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Apr 2025Grant (prize money)$2.2M
- Jun 2023Grant (prize money)$3M
- May 2023Series A$8M
- May 2023Grant (prize money)$605.5K
Founders & team
Investors
Orlando Health, Colle Capital, Frontier Venture Capital, NIH, HHS, Bruggere Capital
Tech stack
WixReactGoogle CloudPolyfillLodashAhrefs
#12
Seed · Los Angeles, California · founded 2020 · 5 employees$1.2Mraised▾
Seed · Los Angeles, California · founded 2020 · 5 employees
Provider of platform technology to prevent diabetes. It offers a conserved pathway for physiologically induced tissue regeneration that will restore beta-cell function and induce homeostatic cell fitness competition for the maintenance of functional beta-cell mass.
Funding rounds
- Mar 2026Seed$900K
- Jul 2024Grant (prize money)$295.3K
Founders & team
Investors
HHS, Healthspan Capital
Funding & investor landscape
$3Btotal disclosed funding
129companies funded
440disclosed rounds
2rounds last 90 days
Most active investors
Y Combinator4 rounds
Notable founders
Mark Attanasio
Co-Founder · TORL BioTherapeutics
Yi Lo
CEO · Aneuvo
Ken Schultz
Chairman & CEO · Trethera
Sumeet Singh
Founder & CEO · LighthouseAI
William Lowry
Co-Founder & President · Pelage Pharmaceuticals
Heather Christofk
Co-Founder · Pelage Pharmaceuticals
Yair Rivenson
Co-Founder & CEO · Pictor Labs
Aydogan Ozcan
Co-Founder · Pictor Labs
Ilya Rachman
Co-Founder & CEO · Immix Biopharma
April Pyle
Co-Founder · MyoGene Bio
Melissa Spencer
Co-Founder · MyoGene Bio
Anthony Arnold
President & Chief Executive Officer · Sensydia
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share shrank from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements are intensifying — both jumped from ~3 to 62 papers, driving advancements' share from 29% to 35%.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern is rising steadily — papers tripled from 15 to 45 across U.S. biotechnology institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Life Sciences companies are there in Los Angeles, United States?
Radar tracks 286 indexable Life Sciences companies headquartered in Los Angeles, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Los Angeles, United States?
The Life Sciences companies in Los Angeles, United States on this list have raised a combined $3B in disclosed equity funding across 129 funded companies.
Which is the highest-funded Life Sciences company in Los Angeles, United States?
ACELYRIN is the highest-funded Life Sciences company in Los Angeles, United States, with $550M in disclosed equity funding.
How many Life Sciences companies in Los Angeles, United States are funded?
129 of the 286 Life Sciences companies in Los Angeles, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Los Angeles, United States?
None of the Life Sciences companies in Los Angeles, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Los Angeles, United States Life Sciences companies?
The most active investors in Los Angeles, United States Life Sciences companies on this list include HHS, NIH, National Science Foundation, IndieBio, Leonhardt Ventures.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.